{
    "Trade/Device Name(s)": [
        "BioSieve\u2122 Fentanyl FIA Home Test Kit",
        "BioSieve\u2122 Fentanyl FIA Pro Test Kit",
        "BioSieve\u2122 Toxismart Reader"
    ],
    "Submitter Information": "VivaChek Biotech (Hangzhou) Co., Ltd.",
    "510(k) Number": "K241869",
    "Predicate Device Reference 510(k) Number(s)": [
        "K240124"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "NGL",
        "KHO"
    ],
    "Summary Letter Date": "June 27, 2024",
    "Summary Letter Received Date": "June 27, 2024",
    "Submission Date": "September 27, 2024",
    "Regulation Number(s)": [
        "21 CFR 862.3650",
        "21 CFR 862.2560"
    ],
    "Regulation Name(s)": [
        "Opiate Test System",
        "Fluorometer for clinical use"
    ],
    "Analyte Class(es)": [
        "toxicology",
        "chemistry"
    ],
    "Analyte(s)": [
        "Fentanyl"
    ],
    "Specimen Type(s)": [
        "Urine"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "BioSieve\u2122 Toxismart Reader"
    ],
    "Method(s)/Technology(ies)": [
        "Fluorescence immunoassay (FIA)",
        "Competitive immunochromatography",
        "Immunofluorescence analyzer"
    ],
    "Methodologies": [
        "Competitive binding immunoassay",
        "Immunochromatographic assay"
    ],
    "Submission Type(s)": [
        "Kit",
        "Analyzer",
        "Cassette",
        "Reader"
    ],
    "Document Summary": "FDA 510(k) summary for BioSieve\u2122 Fentanyl FIA Home/Pro Test Kit and Toxismart Reader for qualitative determination of fentanyl in urine using fluorescence immunoassay and portable reader",
    "Indications for Use Summary": "For qualitative detection of fentanyl in human urine at 1.0 ng/mL cutoff using the BioSieve\u2122 Toxismart Reader; provides preliminary results, requires confirmatory chemical analysis by GC/MS or LC/MS.",
    "fda_folder": "Toxicology"
}